ANI Pharmaceuticals announced that it received U.S. FDA approval for the Abbreviated New Drug Application for Indomethacin Oral Suspension, USP. ANI’s Indomethacin OS is the generic version of the Reference Listed Drug Indocin Oral Suspension. The current annual U.S. market for Indomethacin OS is approximately $4.1M, according to the latest estimates from IQVIA/IMS Health, a healthcare data and analytics provider.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANIP:
